TRK 530

Drug Profile

TRK 530

Latest Information Update: 03 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toray
  • Developer Kaken Pharmaceutical; Toray
  • Class Antirheumatics; Bisphosphonates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bone disorders; Rheumatoid arthritis

Most Recent Events

  • 03 Apr 2007 No development reported - Phase-II for Rheumatoid arthritis in Japan (PO)
  • 03 Apr 2007 No development reported - Preclinical for Bone disorders in Japan (PO)
  • 28 Jun 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top